Myocardial Injury
3
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
U
SOJOURNApproved
sevoflurane
Unknown CompanyGeneral Anesthetic [EPC]inhalation2007
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Alliance PharmaceuticalsUK - Wiltshire
1 program1
Uncultured, autologous, adipose-derived regenerative cellsPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbottSevoflurane
Alliance PharmaceuticalsUncultured, autologous, adipose-derived regenerative cells
AbbottSevoflurane
Clinical Trials (3)
Total enrollment: 4,186 patients across 3 trials
Continuous Versus Repetitive Sevoflurane Administration for Preconditioning
Start: Jan 2005Est. completion: May 200750 patients
Phase 4Completed
Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate.
Start: Nov 2024Est. completion: Dec 202536 patients
Phase 2Recruiting
Clinical Practice of Inhalation Anesthesia With Sevoflurane in China
Start: Jul 2012Est. completion: Jul 20134,100 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 4,186 patients
3 companies competing in this space